BioSpace News Archive

Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today the appointment of June Lee, M.D. and Troy Ignelzi as new independent members of the Abivax Board of Directors.

Novel patient-led research initiative will measure the true impact of skin diseases globally

Voyager Therapeutics, Inc. has entered into employment agreements with Jacquelyn Fahey Sandell and another newly hired employee that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.

Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer, will present at the SHARE™ Series Monday Management Update for investors on Monday, July 17, 2023, at 11:30 am ET.

Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream in children with atopic dermatitis.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an exercise price per share of $21.88, which was the closing price on July 10, 2023, and restricted stock units to acquire a total of 10,300 shares of the Company’s common stock.

CVRx, Inc. announced that it plans to release second quarter 2023 financial and operating results after market close on Tuesday, July 25th, 2023.

Arthrosi Therapeutics, a clinical-stage biotechnology company, announced the successful securing of $75 million in Series D financing.

Verve Medical, Inc. (Verve) announced today that the Company has received approval from the US Food & Drug Administration (FDA) to initiate its Natural Orifice via renal pelvis denervation (NOVEL- Denervation) Pivotal IDE trial for the treatment of uncontrolled hypertension to lower blood pressure.

Sciwind Biosciences Co., Ltd. announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide in Molecular Metabolism.